Latest Biotech News

Pfizer broadened the clinical case for its monthly obesity GLP-1 treatment berobenatide with new mid-stage data on a weekly-to-monthly dosing path. The company’s data were presented at the...

Roche said it plans to start a Phase 2 trial this year testing an obesity-drug combination of petrelintide and enicepatide. The company framed the pairing as an opportunity to combine a...

Abivax’s shares swung after the company’s Phase 3 ABTECT maintenance trial posted positive topline results for obefazimod in ulcerative colitis, but investors focused on malignancies seen in...

GRWD5769, an oral ERAP1 inhibitor, combined with cemiplimab showed durable activity across multiple Phase 1b expansion cohorts in solid tumors with secondary anti–PD-1 resistance and in MSS-CRC....

Pfizer presented data indicating berobenatide’s long-acting monthly GLP-1 regimen delivers efficacy in patients with both obesity and diabetes, reinforcing the drug’s positioning after its Metsera...

A German observational analysis using health insurance claims data linked discontinuation of dental care to worsening systemic diseases in homebound elderly patients. Published under the InSEMaP...

Researchers engineered a portable CRISPR-based assay for mpox detection designed for field use following the 2025 outbreak in Sierra Leone. The work, led by Gopal, Abay, and Payne, aims to improve...

ABBV-706, a SEZ6-targeting antibody-drug conjugate, began first-in-human evaluation in patients with advanced solid tumors. The clinical update is logged in a Journal of Clinical Oncology...

A new saliva-based biomarker strategy is being advanced for oral potentially malignant disorders, with reported links between oral precancer status and clinical outcomes. The study, led by Chen...

Boehringer Ingelheim’s obesity shot, survodutide (licensed from Zealand Pharma), saw notable Phase 3 discontinuations attributed to side effects, according to SYNCHRONIZE-1 reporting referenced in...

Eli Lilly disclosed additional safety and tolerability data for retatrutide at the American Diabetes Association meeting, including counts of arrhythmias and major cardiovascular complications...

Roche plans to initiate a Phase 2 trial combining petrelintide and enicepatide later this year, according to ADA26 reporting. The companies are positioning the dual-incretin approach as a path to...

Pfizer presented updated clinical data supporting monthly dosing of berobenatide for obesity, following earlier signals from VESPER-3. In the study, patients transitioned from weekly dosing to...

At ADA26, Pfizer added additional framing for berobenatide’s use in obesity and diabetes, citing data presented alongside its long-acting GLP-1 receptor agonist program. The coverage also ties the...

Ona secured an $86.6 million venture round positioned among Spain’s largest biotech financings, according to Biocentury Finance reporting. The capital injection underscores continued appetite for...

Forbion announced the hire of John McDonald as an operating partner focused on business development and M&A, with prior experience including corporate business development leadership at Novo...

An early first-in-human study is underway for ABBV-706, a SEZ6-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors. The program’s Journal of Clinical Oncology...

SYS6043, a B7-H3/Top1 antibody-drug conjugate (ADC), began Phase 1 dose escalation in solid tumor malignancies, according to the study listing. The start of dose escalation highlights ongoing...

Researchers engineered a portable CRISPR-based assay for mpox detection in the wake of the 2025 outbreak in Sierra Leone, as described in the report. The approach is aimed at field diagnostics and...

Eli Lilly disclosed additional safety and tolerability data for retatrutide at the American Diabetes Association meeting and in The Lancet, extending results from TRANSCEND-T2D-1. The company...